Interferon-induced changes in pharmacokinetics and tumor uptake of111 in-labeled antimelanoma antibody 96.5 in melanoma patients

Michael G. Rosenblum, Lamk M. Lamki, James L. Murray, Dennis J. Carlo, Jordan U. Gutterman

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

The type I interferons [both partially purified human leukocyte interferon (HuIFN-α) and recombinant alpha interferon] and the type II interferons have been shown to increase the expression of tumor-associated antigens in vitro. To determine whether HuIFN-α could increase tumor acquisition of the antimelanoma antibody 96.5 in vivo, five patients with metastatic malignant melanoma were treated with HuIFN-α at a dose of 3 × 106 units daily by im administration. Twenty-four hours after the first dose of HuIFN-α, 1 mg of antibody 96.5 labeled with 5 mCi of 111In was coadministered with 19 mg of unlabeled 96.5. Five patients matched for metastatic site and lesion size who had not received HuIFN-α were also given a dose of 5 mCi of radiolabeled 96.5 at the same total antibody dose (20 mg). In patients treated with HuIFN-α, there was a statistically significant increase in the plasma half-life of the 111In label (39.7 ± 3.3 hr) compared to the untreated control group (29.8 ± 3.2 hr). In addition, there was an increase in the apparent volume of distribution of the antibody in the HuIFN-α group (5.56 ± 0.67 L) compared to controls (3.15 ± 0.5 L) suggesting both an increased immediate extravascular distribution of radiolabeled antibody and a decrease in the subsequent rate of clearance of antibody from plasma. These two phenomena result in a 28% decrease in the area under the concentration curve in the HuIFN-α-treated group compared to controls. Computer analysis of whole-body scans from patients showed a threefold increase in radiolabeled antibody distributed to tumor relative to blood pool but no change in organ: blood ratios for liver, spleen, bone, or kidney compared to controls. This pilot study suggests that treatment of patients with HuIFN-α results in an improved distribution of radiolabeled antibody to tumor target without a concomitant increase of label in normal nontarget tissues. In addition, this change in whole-body distribution of antibody is manifested by changes in the pharmacokinetic parameters measured for monoclonal antibody. [J Natl Cancer Inst 1988;80:160-165]

Original languageEnglish
Pages (from-to)160-165
Number of pages6
JournalJournal of the National Cancer Institute
Volume80
Issue number3
DOIs
Publication statusPublished - Apr 6 1988

Fingerprint

Interferons
Leukocytes
Melanoma
Pharmacokinetics
Antibody
Interferon-alpha
Antibodies
Tumors
Tumor
Neoplasms
Dose
Blood
Plasma
Interferon-gamma
Human
Labels
Decrease
Monoclonal Antibody
Neoplasm Antibodies
Kidney

ASJC Scopus subject areas

  • Statistics, Probability and Uncertainty
  • Applied Mathematics
  • Physiology (medical)
  • Radiology Nuclear Medicine and imaging
  • Oncology
  • Cancer Research

Cite this

Interferon-induced changes in pharmacokinetics and tumor uptake of111 in-labeled antimelanoma antibody 96.5 in melanoma patients. / Rosenblum, Michael G.; Lamki, Lamk M.; Murray, James L.; Carlo, Dennis J.; Gutterman, Jordan U.

In: Journal of the National Cancer Institute, Vol. 80, No. 3, 06.04.1988, p. 160-165.

Research output: Contribution to journalArticle

Rosenblum, Michael G. ; Lamki, Lamk M. ; Murray, James L. ; Carlo, Dennis J. ; Gutterman, Jordan U. / Interferon-induced changes in pharmacokinetics and tumor uptake of111 in-labeled antimelanoma antibody 96.5 in melanoma patients. In: Journal of the National Cancer Institute. 1988 ; Vol. 80, No. 3. pp. 160-165.
@article{c3d54a2b24de4ebfa822143df2f588fd,
title = "Interferon-induced changes in pharmacokinetics and tumor uptake of111 in-labeled antimelanoma antibody 96.5 in melanoma patients",
abstract = "The type I interferons [both partially purified human leukocyte interferon (HuIFN-α) and recombinant alpha interferon] and the type II interferons have been shown to increase the expression of tumor-associated antigens in vitro. To determine whether HuIFN-α could increase tumor acquisition of the antimelanoma antibody 96.5 in vivo, five patients with metastatic malignant melanoma were treated with HuIFN-α at a dose of 3 × 106 units daily by im administration. Twenty-four hours after the first dose of HuIFN-α, 1 mg of antibody 96.5 labeled with 5 mCi of 111In was coadministered with 19 mg of unlabeled 96.5. Five patients matched for metastatic site and lesion size who had not received HuIFN-α were also given a dose of 5 mCi of radiolabeled 96.5 at the same total antibody dose (20 mg). In patients treated with HuIFN-α, there was a statistically significant increase in the plasma half-life of the 111In label (39.7 ± 3.3 hr) compared to the untreated control group (29.8 ± 3.2 hr). In addition, there was an increase in the apparent volume of distribution of the antibody in the HuIFN-α group (5.56 ± 0.67 L) compared to controls (3.15 ± 0.5 L) suggesting both an increased immediate extravascular distribution of radiolabeled antibody and a decrease in the subsequent rate of clearance of antibody from plasma. These two phenomena result in a 28{\%} decrease in the area under the concentration curve in the HuIFN-α-treated group compared to controls. Computer analysis of whole-body scans from patients showed a threefold increase in radiolabeled antibody distributed to tumor relative to blood pool but no change in organ: blood ratios for liver, spleen, bone, or kidney compared to controls. This pilot study suggests that treatment of patients with HuIFN-α results in an improved distribution of radiolabeled antibody to tumor target without a concomitant increase of label in normal nontarget tissues. In addition, this change in whole-body distribution of antibody is manifested by changes in the pharmacokinetic parameters measured for monoclonal antibody. [J Natl Cancer Inst 1988;80:160-165]",
author = "Rosenblum, {Michael G.} and Lamki, {Lamk M.} and Murray, {James L.} and Carlo, {Dennis J.} and Gutterman, {Jordan U.}",
year = "1988",
month = "4",
day = "6",
doi = "10.1093/jnci/80.3.160",
language = "English",
volume = "80",
pages = "160--165",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Interferon-induced changes in pharmacokinetics and tumor uptake of111 in-labeled antimelanoma antibody 96.5 in melanoma patients

AU - Rosenblum, Michael G.

AU - Lamki, Lamk M.

AU - Murray, James L.

AU - Carlo, Dennis J.

AU - Gutterman, Jordan U.

PY - 1988/4/6

Y1 - 1988/4/6

N2 - The type I interferons [both partially purified human leukocyte interferon (HuIFN-α) and recombinant alpha interferon] and the type II interferons have been shown to increase the expression of tumor-associated antigens in vitro. To determine whether HuIFN-α could increase tumor acquisition of the antimelanoma antibody 96.5 in vivo, five patients with metastatic malignant melanoma were treated with HuIFN-α at a dose of 3 × 106 units daily by im administration. Twenty-four hours after the first dose of HuIFN-α, 1 mg of antibody 96.5 labeled with 5 mCi of 111In was coadministered with 19 mg of unlabeled 96.5. Five patients matched for metastatic site and lesion size who had not received HuIFN-α were also given a dose of 5 mCi of radiolabeled 96.5 at the same total antibody dose (20 mg). In patients treated with HuIFN-α, there was a statistically significant increase in the plasma half-life of the 111In label (39.7 ± 3.3 hr) compared to the untreated control group (29.8 ± 3.2 hr). In addition, there was an increase in the apparent volume of distribution of the antibody in the HuIFN-α group (5.56 ± 0.67 L) compared to controls (3.15 ± 0.5 L) suggesting both an increased immediate extravascular distribution of radiolabeled antibody and a decrease in the subsequent rate of clearance of antibody from plasma. These two phenomena result in a 28% decrease in the area under the concentration curve in the HuIFN-α-treated group compared to controls. Computer analysis of whole-body scans from patients showed a threefold increase in radiolabeled antibody distributed to tumor relative to blood pool but no change in organ: blood ratios for liver, spleen, bone, or kidney compared to controls. This pilot study suggests that treatment of patients with HuIFN-α results in an improved distribution of radiolabeled antibody to tumor target without a concomitant increase of label in normal nontarget tissues. In addition, this change in whole-body distribution of antibody is manifested by changes in the pharmacokinetic parameters measured for monoclonal antibody. [J Natl Cancer Inst 1988;80:160-165]

AB - The type I interferons [both partially purified human leukocyte interferon (HuIFN-α) and recombinant alpha interferon] and the type II interferons have been shown to increase the expression of tumor-associated antigens in vitro. To determine whether HuIFN-α could increase tumor acquisition of the antimelanoma antibody 96.5 in vivo, five patients with metastatic malignant melanoma were treated with HuIFN-α at a dose of 3 × 106 units daily by im administration. Twenty-four hours after the first dose of HuIFN-α, 1 mg of antibody 96.5 labeled with 5 mCi of 111In was coadministered with 19 mg of unlabeled 96.5. Five patients matched for metastatic site and lesion size who had not received HuIFN-α were also given a dose of 5 mCi of radiolabeled 96.5 at the same total antibody dose (20 mg). In patients treated with HuIFN-α, there was a statistically significant increase in the plasma half-life of the 111In label (39.7 ± 3.3 hr) compared to the untreated control group (29.8 ± 3.2 hr). In addition, there was an increase in the apparent volume of distribution of the antibody in the HuIFN-α group (5.56 ± 0.67 L) compared to controls (3.15 ± 0.5 L) suggesting both an increased immediate extravascular distribution of radiolabeled antibody and a decrease in the subsequent rate of clearance of antibody from plasma. These two phenomena result in a 28% decrease in the area under the concentration curve in the HuIFN-α-treated group compared to controls. Computer analysis of whole-body scans from patients showed a threefold increase in radiolabeled antibody distributed to tumor relative to blood pool but no change in organ: blood ratios for liver, spleen, bone, or kidney compared to controls. This pilot study suggests that treatment of patients with HuIFN-α results in an improved distribution of radiolabeled antibody to tumor target without a concomitant increase of label in normal nontarget tissues. In addition, this change in whole-body distribution of antibody is manifested by changes in the pharmacokinetic parameters measured for monoclonal antibody. [J Natl Cancer Inst 1988;80:160-165]

UR - http://www.scopus.com/inward/record.url?scp=0023888357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023888357&partnerID=8YFLogxK

U2 - 10.1093/jnci/80.3.160

DO - 10.1093/jnci/80.3.160

M3 - Article

C2 - 3346909

AN - SCOPUS:0023888357

VL - 80

SP - 160

EP - 165

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 3

ER -